Cardinal Health stock soars to all-time high of $130.1

Cardinal Health Inc (NYSE:CAH). shares have reached an unprecedented peak, with the stock hitting an all-time high of $130.1. The $31.2 billion healthcare provider has shown remarkable momentum, with InvestingPro data revealing a impressive 32% surge over the past six months. This milestone underscores the company's robust performance over the past year, which has seen the stock price soar, reflecting a significant 1-year change of 21.88%. Investors have shown increased confidence in Cardinal Health's market position and growth prospects, propelling the stock to new heights and setting a record in the company's trading history. The achievement of this all-time high serves as a testament to Cardinal Health's strategic initiatives and its resilience in a competitive healthcare landscape. Notable is the company's 43-year track record of consistent dividend payments, while InvestingPro analysis suggests the stock remains undervalued despite its recent gains. For deeper insights, investors can access 14 additional ProTips and comprehensive analysis through InvestingPro's detailed research report.

In other recent news, Cardinal Health has raised its earnings forecast for fiscal year 2025 to the higher end of the projected range of $7.75 to $7.90, primarily due to strength in the Pharmaceutical (TADAWUL:2070) segment. The company's stock rating has been upgraded by multiple firms, including TD Cowen from Hold to Buy, Evercore ISI from In Line to Outperform, and BofA Securities from Neutral to Buy. These upgrades reflect expectations of Cardinal Health outperforming current earnings projections and potential for higher long-term guidance.

Recent acquisitions are also a focus for the company. Cardinal Health announced plans to acquire Integrated Oncology Network for $1.1 billion and is also planning to acquire majority equity interests in The GI Alliance Holdings, LLC, and Advanced Diabetes Supply Group. To partially finance these acquisitions, the company successfully raised $2.9 billion through a public offering of senior notes.

Furthermore, T2 Biosystems (NASDAQ:TTOO) has decided to license its sepsis detection technology following a commercial agreement with Cardinal Health. These are all recent developments that highlight the ongoing growth and strategic initiatives of Cardinal Health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.